Goldman Sachs Highlights Stocks to Buy, Including Alibaba and Ulta Beauty
Goldman Sachs analysts recommend buying Alibaba (64% EPS growth by 2027), Ulta Beauty (market share gains), Burlington Stores (strong margins), Viking Holdings (resilient pricing), and Aecom (undervalued despite AI concerns).
How this was made

The 30-second read
Why it matters
Analyst upgrades with specific EPS targets can prompt re‑rating by other firms and trigger trading activity.
Market read
The recommendations target mid‑cap stocks across sectors, offering potential trade ideas for investors seeking growth catalysts.
What to watch
Regulatory risks for Alibaba and macro‑economic headwinds for US retailers could limit gains.
Background
Goldman Sachs published a list of stocks it deems attractive, providing fresh EPS forecasts and buy recommendations.
Ticker impact
Goldman Sachs forecasts Alibaba EPS recovery of 64% FY2027 and 33% FY2028, a new analyst projection.
Mid-term price appreciation expected.
Analyst upgrade with specific EPS targets can drive buying interest.
Goldman Sachs calls Ulta Beauty a strong buy after recent earnings, citing over‑penalization.
Short‑term rally possible.
Analyst buy rating with valuation view can trigger price move.
Goldman highlights Burlington Stores as a buying opportunity despite mixed quarterly results.
Limited impact, modest upside.
Mixed results reduce catalyst strength.
Goldman recommends Viking Holdings despite a 20% share decline, citing pricing strength.
Potential rebound over weeks.
Analyst confidence in pricing may attract buyers.
Goldman notes Aecom faces AI‑related valuation pressure, implying a negative outlook.
Downside risk in near term.
Critique without new positive catalyst.
Market effects
AI and cloud growth expectations boost Chinese e‑commerce and US retail sectors.
Positive outlook for US consumer discretionary and Chinese tech exposure.
Analyst calls may influence global fund allocations to these stocks.
Counterpoint
Skeptics may argue valuations are already stretched and AI concerns could outweigh upside.
Key entities
- Research FirmGoldman Sachs
Provider of the analyst recommendations.

